A new mobility ecosystem will personalize every journey by 2030
27.4.2023 09:35:00 EEST | Business Wire | Press release
Management and technology consultancy BearingPoint’s latest study on mobility sees a personalized travel experience by 2030 that shifts the priorities for all stakeholders in a new mobility ecosystem. The study, Mobility 2030, says all players will battle over customer and value chain data, and service offerings must address national as well as urban and rural demand patterns.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230426005716/en/
BearingPoint’s latest study on mobility sees a personalized travel experience by 2030 that shifts the priorities for all stakeholders in a new mobility ecosystem. (Graphic: Business Wire)
“The automotive industry must respond to the human-centric mobility trend to stay ahead of the competition by maintaining its strategic position as the prime touchpoint to the customer. The industry must provide customers with truly personalized offerings, focus on collecting complex data to derive actionable insights, and orchestrate an ecosystem of partners that embraces new technologies,” said Dr. Stefan Penthin, Global Leader Automotive and Industrial Manufacturing at BearingPoint.
The study is the first in a series of three on mobility and drew from BearingPoint’s internal research, the views of clients across all industry segments and input from the consultancy’s segment and technology leaders. While the automotive industry is the focus, the study examines how all segments will be active in the new mobility ecosystem, from manufacturers and transportation providers to energy suppliers, government organizations, and insurance companies.
By 2030, the study projects that approximately 23% of all megacity trips will be through shared, on-demand mobility offerings (up from just 8% in 2021). By 2030, each player will be part of a demanding new infrastructure and alliance-ecosystem relationships that deliver multimodal journeys with diverse powertrains. Mobility will be consumed as a service, so access to data will be key. On-demand services mean all players will compete to acquire, analyze, and exploit customer data so they can react to changing travel patterns.
“In the journey to 2030, the transportation experience will become individualized, and new infrastructure, services, and relationships will be needed. Providers must be more user-centered and cater to rural and urban demands. Ultimately both utility companies and public transportation organizations will have a new and larger role,” said Marion Schulte, Global Leader Utilities, Postal and Transportation at BearingPoint.
Mobility that maximizes security, personal well-being, and sustainability
Various modes of travel will become integrated, enabling urban and rural intermodal transport hubs. Customers will demand mobility that maximizes security, personal well-being, and sustainability. Risk profiles will diverge for different usage and regions, the study foresees. According to EU statistics, 17 of the 20 busiest air routes in Europe cover distances of less than 434 miles, distances where intercity trains can offer faster, cleaner, and more sustainable journeys.
“As citizens demand greater availability, quality, and flexibility from mobility services, public transportation policy will evolve. Governments should ensure equal access to transport networks for all citizens, and the various modes of travel must be carefully integrated with safety, security, and personal well-being key priorities. Mobility policies should also be designed to maximize citizens productivity, both in terms of working and non-working time,” said Andrew Montgomery, Global Leader Government and Public Sector.
For more details and insights, you can download the study here: https://www.bearingpoint.com/en/insights-events/insights/destination-2030-what-happens-when-every-journey-is-personalized/
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provides IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230426005716/en/
Contact information
Press contact
Alexander Bock
Global Senior Manager Communications
Telephone: +49 89 540338029
E-Mail: alexander.bock@bearingpoint.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom